SCHEMBL498341

SCHEMBL498341

O=C(O)C(C(=O)O)n1cccc1

nearest known ligand 0.43

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
TDP1 Q9NUW8 2/20 0.34
POLB P06746 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
HPGD P15428 3/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
HTT P42858 1/20 0.32
TSHR P16473 2/20 0.31
CYP2D6 P10635 1/20 0.31
GAA P10253 1/20 0.31
SRC P12931 1/20 0.31
PPARG P37231 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27508846 0.76 PIN1 (0.40) HSD17B10NPSR1TDP1POLBSMN1; SMN2
SCHEMBL18258606 0.74 HSD17B10 (0.42) HSD17B10NPSR1GAA
SCHEMBL735831 0.74 HSD17B10 (0.42) HSD17B10NPSR1GAA
SCHEMBL7936004 0.74 HSD17B10 (0.42) HSD17B10NPSR1TDP1POLBSMN1; SMN2
SCHEMBL11397824 0.72 HSD17B10 (0.41) HSD17B10NPSR1TDP1POLBSMN1; SMN2
SCHEMBL28059371 0.72 HSD17B10 (0.41) HSD17B10NPSR1TDP1POLBSMN1; SMN2
SCHEMBL14247750 0.69 RAB9A (0.39) HSD17B10NPSR1TDP1POLBSMN1; SMN2
SCHEMBL2793671 0.69 NPSR1 (0.57) HSD17B10NPSR1POLBHPGDHTT
SCHEMBL14248374 0.69 RAB9A (0.39) HSD17B10NPSR1TDP1POLBSMN1; SMN2
SCHEMBL18258607 0.69 RAB9A (0.39) HSD17B10NPSR1TDP1POLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2058300-B1 SUCCINIC ACID DIESTER DERIVATIVE, PROCESS FOR PRODUCTION THEREOF, AND USE OF THE DERIVATIVE IN THE PRODUCTION OF PHARMACEUTICAL PREPARATION DAINIPPON SUMITOMO PHARMA CO (JP) 2013-01-09 EP disclosed
US-8106230-B2 Succinic acid diester derivative, process for production thereof, and use of the derivative in the production of pharmaceutical preparation DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-01-31 US disclosed
US-8030486-B2 Succinic acid diester derivative, process for production thereof, and use of the derivative in the production of pharmaceutical preparation DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-10-04 US disclosed
US-20110046373-A1 SUCCINIC ACID DIESTER DERIVATIVE, PROCESS FOR PRODUCTION THEREOF, AND USE OF THE DERIVATIVE IN THE PRODUCTION OF PHARMACEUTICAL PREPARATION INAGAKI TAKASHI 2011-02-24 US disclosed
US-20100076203-A1 Succinic acid diester derivative, process for production thereof, and use of the derivative in the production of pharmaceutical preparation DAINIPPON SUMITOMO PHARMA CO., LTD. 2010-03-25 US disclosed
EP-2058300-A1 SUCCINIC ACID DIESTER DERIVATIVE, PROCESS FOR PRODUCTION THEREOF, AND USE OF THE DERIVATIVE IN THE PRODUCTION OF PHARMACEUTICAL PREPARATION Dainippon Sumitomo Pharma Co., Ltd. (JP) 2009-05-13 EP disclosed
EP-0520320-B1 Tetrahydropyrrolo[1,2-a]pyrazine-4-spiro-3'-pyrrolidine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same DAINIPPON PHARMACEUTICAL CO (JP) 1997-09-10 EP disclosed
EP-0520320-A2 Tetrahydropyrrolo 1,2-a pyrazine-4-spiro-3'-pyrrolidine derivatives, processes for the preparation thereof and pharaceutical compositions containing the same DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 1992-12-30 EP disclosed
US-4421914-A IMMUNE FUNCTION REGULATORS TEIJIN LIMITED (JP) 1983-12-20 US disclosed
EP-0049902-A2 Novel thiazolo(3,2-a)pyrimidines, derivatives thereof, processes for production thereof, and pharmaceutical use thereof TEIJIN LIMITED (JP) 1982-04-21 EP disclosed
US-4148998-A ANTIBIOTICS YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) 1979-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046373-A1 SUCCINIC ACID DIESTER DERIVATIVE, PROCESS FOR PRODUCTION THEREOF, AND USE OF THE DERIVATIVE IN THE PRODUCTION OF PHARMACEUTICAL PREPARATION SUCNR1, DLST, SHMT2 HSD17B10 257/4885NPSR1 2027/4885TDP1 4164/4885
US-20100076203-A1 Succinic acid diester derivative, process for production thereof, and use of the derivative in the production of pharmaceutical preparation SUCNR1, DLST, SHMT2 HSD17B10 257/4885NPSR1 2027/4885TDP1 4164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.